logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
9/12/2018 6:21:11 AM Biohaven Submits IND For BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist For Treatment Of Migraine
9/12/2018 3:01:05 AM Biohaven Appoints Bob Repella To Board
9/6/2018 3:01:39 AM Biohaven Highlights Positive Results From Study 301 And Study 302 Of Rimegepant
9/5/2018 3:01:48 AM Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca
8/16/2018 3:03:42 AM Biohaven Reports Positive Results From Proof Of Concept Clinical Trial Evaluating Effect Of BHV-0223
8/15/2018 8:03:34 AM William Blair Is Cutting Biohaven Pharmaceutical Holding Co Ltd. (BHVN) FY20 Estimate To -2.47 From -1.70
8/15/2018 8:03:08 AM William Blair Is Cutting Biohaven Pharmaceutical Holding Co Ltd. (BHVN) FY19 Estimate To -5.54 From -4.90
8/15/2018 8:02:53 AM William Blair Is Cutting Biohaven Pharmaceutical Holding Co Ltd. (BHVN) FY18 Estimate To -5.75 From -5.51
8/1/2018 3:00:35 AM First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial
7/24/2018 3:01:22 AM Biohaven Gets FDA May Proceed Letter And Initiates Phase 2/3 Trial Of Trigriluzole In Alzheimer's Disease
6/28/2018 3:03:08 AM Biohaven Expands Rimegepant Development Program
6/18/2018 9:29:32 PM Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Mln
5/9/2018 3:03:47 AM Biohaven Initiates Expanded Access Program For Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets For Patients With ALS
4/22/2018 10:02:53 PM Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits
4/19/2018 3:03:52 AM Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data To Be Released At Investor Event Ith 2018 AAN